{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:42:03Z","timestamp":1792698123690,"version":"4.5.0"},"reference-count":91,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is a complex disease, affecting not just the liver, but also all other organs in the body. Despite an increasing amount of people worldwide developing NAFLD and having it progress to non-alcoholic steatohepatitis (NASH) and potentially cirrhosis, there is still no approved therapy. Therefore, huge efforts are being made to find and develop a successful treatment. One of the special interests is understanding the liver\u2013gut axis and especially the role of bile acids in the progression of NAFLD. Farnesoid X receptor (FXR)-agonists have been approved und used in other liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), and have shown signs of being able to decrease inflammation and potentially steatosis. This review will mainly focus on targets\/ligands that play an important role in bile acid metabolism and give an overview of ongoing clinical as well as pre-clinical trials. With the complexity of the issue, we did not aim at giving a complete review, rather highlighting important targets and potential treatments that could be approved for NAFLD\/NASH treatment within the next few years.<\/jats:p>","DOI":"10.3390\/cells8111358","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T05:18:26Z","timestamp":1572499106000},"page":"1358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression"],"prefix":"10.3390","volume":"8","author":[{"given":"Aline","family":"Gottlieb","sequence":"first","affiliation":[{"name":"Department of Physiology, Johns Hopkins University, Baltimore, MD 21224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Canbay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ruhr University Bochum, University Hospital Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"ref_1","first-page":"662","article-title":"Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries","volume":"15","author":"Seyda","year":"2016","journal-title":"Annu. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.12688\/f1000research.12028.1","article-title":"The role of NAFLD in cardiometabolic disease: An update","volume":"7","author":"Faasse","year":"2018","journal-title":"F1000Research"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: A systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"ref_4","first-page":"434","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/lt.25003","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation","volume":"24","author":"Younossi","year":"2018","journal-title":"Liver Transpl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1128\/aem.45.1.308-309.1983","article-title":"Enhancement of the 7 alpha-dehydroxylase activity of a gram-positive intestinal anaerobe by flavins","volume":"45","author":"Masuda","year":"1983","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/prot.24971","article-title":"Structure and functional characterization of a bile acid 7\u03b1 dehydratase BaiE in secondary bile acid synthesis","volume":"84","author":"Bhowmik","year":"2016","journal-title":"Proteins Struct. Funct. Bioinform."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.26225","article-title":"Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis","volume":"57","author":"Bechmann","year":"2013","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mouzaki, M., Wang, A.Y., Bandsma, R., Comelli, E.M., Arendt, B.M., Zhang, L., Fung, S., Fischer, S.E., McGilvray, I.G., and Allard, J.P. (2016). Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151829"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1021\/bi00135a001","article-title":"Bile acid biosynthesis","volume":"31","author":"Russell","year":"1992","journal-title":"Biochemistry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.apsb.2019.02.004","article-title":"Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters","volume":"9","author":"Sun","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.taap.2013.01.022","article-title":"Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease","volume":"268","author":"Lake","year":"2013","journal-title":"Toxicol. Appl. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10227","DOI":"10.1016\/S0021-9258(18)99213-6","article-title":"Purification and characterization of bile acid-CoA: amino acid N-acyltransferase from human liver","volume":"266","author":"Johnson","year":"1991","journal-title":"J. Boil. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1172\/JCI117722","article-title":"Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter","volume":"95","author":"Shneider","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1042\/cs0610773","article-title":"Urinary Excretion of Bile Acids in Cholestasis: Evidence for Renal Tubular Secretion in Man","volume":"61","author":"Corbett","year":"1981","journal-title":"Clin. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/bs.apha.2015.04.003","article-title":"Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer","volume":"74","author":"Li","year":"2015","journal-title":"Adv. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijgo.2013.02.015","article-title":"Primary bile acids as potential biomarkers for the clinical grading of intrahepatic cholestasis of pregnancy","volume":"122","author":"Chen","year":"2013","journal-title":"Int. J. Gynecol. Obs."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease","volume":"60","author":"Kalhan","year":"2011","journal-title":"Metab. Clin. Exp."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1210\/jc.2017-01397","article-title":"Bile Acid Alterations Are Associated with Insulin Resistance, but Not with NASH, in Obese Subjects","volume":"102","author":"Legry","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/apt.15035","article-title":"Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD","volume":"49","author":"Caussy","year":"2019","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pharmthera.2018.04.005","article-title":"Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease","volume":"190","author":"Yu","year":"2018","journal-title":"Pharm. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MCC.0b013e32835ec9e6","article-title":"Hypoxic liver injury and cholestasis in critically ill patients","volume":"19","author":"Horvatits","year":"2013","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mam.2013.05.001","article-title":"Biosynthesis and trafficking of the bile salt export pump, BSEP: Therapeutic implications of BSEP mutations","volume":"37","author":"Soroka","year":"2014","journal-title":"Mol. Asp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00535-015-1148-y","article-title":"The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease","volume":"51","author":"Okushin","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1074\/jbc.M307363200","article-title":"Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis","volume":"279","author":"Figge","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.1070477","article-title":"Vitamin D Receptor as an Intestinal Bile Acid Sensor","volume":"296","author":"Makishima","year":"2002","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45062","DOI":"10.1074\/jbc.M307145200","article-title":"Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity","volume":"278","author":"Guo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0022-2275(20)30180-2","article-title":"BAREing it all: The adoption of LXR and FXR and their roles in lipid homeostasis","volume":"43","author":"Edwards","year":"2002","journal-title":"J. Lipid Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27703","DOI":"10.1074\/jbc.M302128200","article-title":"Farnesoid X Receptor Regulates Bile Acid-Amino Acid Conjugation","volume":"278","author":"Pircher","year":"2003","journal-title":"J. Boil. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1136\/gutjnl-2016-312975","article-title":"Fibroblast growth factor 15\/19 (FGF15\/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration","volume":"66","author":"Uriarte","year":"2017","journal-title":"Gut"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.apsb.2016.07.008","article-title":"Fatty liver diseases, bile acids, and FXR","volume":"6","author":"Zhu","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.bcp.2013.08.015","article-title":"Bile acid receptors in non-alcoholic fatty liver disease","volume":"86","author":"Li","year":"2013","journal-title":"Biochem. Pharm."},{"key":"ref_40","first-page":"785","article-title":"The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes","volume":"391","author":"Keitel","year":"2010","journal-title":"Boil. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jhep.2016.01.025","article-title":"Metabolic interplay between white, beige, brown adipocytes and the liver","volume":"64","author":"Scheja","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/hep.28707","article-title":"G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice","volume":"65","author":"Donepudi","year":"2017","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.24525","article-title":"The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor \u03ba light-chain enhancer of activated B cells (NF-\u03baB) in mice","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1021\/jm900872z","article-title":"Structure\u2014Activity Relationship Study of Betulinic Acid, A Novel and Selective TGR5 Agonist, and Its Synthetic Derivatives: Potential Impact in Diabetes","volume":"53","author":"Genet","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/hep.28689","article-title":"Vertical sleeve gastrectomy activates GPBAR-1\/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice","volume":"64","author":"Ding","year":"2016","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1074\/jbc.M510258200","article-title":"The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice","volume":"281","author":"Cariou","year":"2006","journal-title":"J. Boil. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1074\/jbc.M115.699504","article-title":"Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet \u03b1 Cells to Promote Glucose Homeostasis","volume":"291","author":"Kumar","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/biof.185","article-title":"Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity","volume":"37","author":"Conde","year":"2011","journal-title":"BioFactors"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/prca.201100052","article-title":"Adipokines: A treasure trove for the discovery of biomarkers for metabolic disorders","volume":"6","author":"Lehr","year":"2012","journal-title":"Proteom. Clin. Appl."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/hep.23046","article-title":"Adipokines in liver diseases","volume":"50","author":"Marra","year":"2009","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diabet.2013.11.004","article-title":"Adiponectin: A multitasking player in the field of liver diseases","volume":"40","author":"Silva","year":"2014","journal-title":"Diabetes Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1042\/CS20100008","article-title":"Significance of serum adiponectin levels in patients with chronic liver disease","volume":"119","author":"Balmer","year":"2010","journal-title":"Clin. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.metabol.2014.09.001","article-title":"Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients","volume":"63","author":"Wree","year":"2014","journal-title":"Metabolism"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1053\/gast.2002.32995","article-title":"Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat","volume":"122","author":"Ikejima","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Huang, H.-H., Lee, W.-J., Chen, S.-C., Chen, T.-F., Lee, S.-D., and Chen, C.-Y. (2019). Bile Acid and Fibroblast Growth Factor 19 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Sleeve Gastrectomy. J. Clin. Med., 8.","DOI":"10.3390\/jcm8060815"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.apsb.2014.12.009","article-title":"Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism","volume":"5","author":"Kwong","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lfs.2016.04.037","article-title":"Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes","volume":"156","author":"Krattinger","year":"2016","journal-title":"Life Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.1074\/jbc.M206749200","article-title":"Bile Acids Enhance Low Density Lipoprotein Receptor Gene Expression via a MAPK Cascade-mediated Stabilization of mRNA","volume":"277","author":"Nakahara","year":"2002","journal-title":"J. Boil. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-0033-1358520","article-title":"Bile Acid-Mediated Control of Liver Triglycerides","volume":"33","author":"Fuchs","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0022-2275(20)31566-2","article-title":"ABCAThe gatekeeper for eliminating excess tissue cholesterol","volume":"42","author":"Oram","year":"2001","journal-title":"J. Lipid Res."},{"key":"ref_64","unstructured":"Cham, S.L. (2015). High Density Lipoproteins: From Biological Understanding to Clinical Exploitation, Springer. Handbook of Experimental Pharmacology."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Li, G., Thomas, A.M., Williams, J.A., Kong, B., Liu, J., Inaba, Y., Xie, W., and Guo, G.L. (2012). Farnesoid X Receptor Induces Murine Scavenger Receptor Class B Type I via Intron Binding. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035895"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/liv.12456","article-title":"Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal","volume":"35","author":"Schmitt","year":"2015","journal-title":"Liver Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mam.2017.06.002","article-title":"Interactions between gut bacteria and bile in health and disease","volume":"56","author":"Long","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1194\/jlr.M075713","article-title":"Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: A potential role for bile acids","volume":"58","author":"Janssen","year":"2017","journal-title":"J. Lipid Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3164\/jcbn.18-116","article-title":"Green tea polyphenol (epigallocatechin-3-gallate) improves gut dysbiosis and serum bile acids dysregulation in high-fat diet-fed mice","volume":"65","author":"Ushiroda","year":"2019","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Appleby, R.N., Moghul, I., Khan, S., Yee, M., Manousou, P., Neal, T.D., and Walters, J.R.F. (2019). Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211348"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00535-015-1104-x","article-title":"Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis","volume":"51","author":"Namisaki","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"108938","DOI":"10.1016\/j.biopha.2019.108938","article-title":"Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease","volume":"115","author":"Gheibi","year":"2019","journal-title":"Biomed. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1194\/jlr.M027433","article-title":"Metabolomics reveals an essential role for peroxisome proliferator-activated receptor \u03b1 in bile acid homeostasis","volume":"53","author":"Li","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.it.2007.09.003","article-title":"Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms","volume":"28","author":"Straus","year":"2007","journal-title":"Trends Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/138920112799095310","article-title":"Methodologies for investigating natural medicines for the treatment of nonalcoholic fatty liver disease (NAFLD)","volume":"13","author":"Kim","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.dld.2013.10.021","article-title":"The bile acid TGR5 membrane receptor: From basic research to clinical application","volume":"46","author":"Duboc","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bph.12158","article-title":"Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release","volume":"169","author":"Ullmer","year":"2013","journal-title":"Br. J. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1152\/ajpgi.00300.2018","article-title":"Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice","volume":"316","author":"Finn","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-17-0557","article-title":"INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function","volume":"238","author":"Comeglio","year":"2018","journal-title":"J. Endocrinol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The Fatty Acid\u2013Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients with Nonalcoholic Fatty Liver Disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9201","DOI":"10.1021\/acs.jmedchem.6b01126","article-title":"Discovery of 3\u03b1, 7\u03b1, 11\u03b2-Trihydroxy-6\u03b1-ethyl-5\u03b2-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders","volume":"59","author":"Pellicciari","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.apsb.2016.11.005","article-title":"A novel class of apical sodium--dependent bile salt transporter inhibitors: 1-(2,4-bifluorophenyl)-7-dialkylamino-1,8-naphthyridine-3-carboxamides","volume":"7","author":"Liu","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Salic, K., Kleemann, R., Wilkins-Port, C., McNulty, J., Verschuren, L., and Palmer, M. (2019). Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-\/-.Leiden mice. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218459"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41401-018-0195-3","article-title":"A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters","volume":"40","author":"Ge","year":"2019","journal-title":"Acta Pharm. Sin."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/11\/1358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:30:38Z","timestamp":1760189438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/11\/1358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":91,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["cells8111358"],"URL":"https:\/\/doi.org\/10.3390\/cells8111358","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,30]]}}}